nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Dactinomycin—testicular cancer	0.0904	0.193	CbGbCtD
Dihydroergotamine—CYP3A4—Ifosfamide—testicular cancer	0.0639	0.137	CbGbCtD
Dihydroergotamine—ABCB1—Vinblastine—testicular cancer	0.0566	0.121	CbGbCtD
Dihydroergotamine—ABCB1—Cisplatin—testicular cancer	0.0519	0.111	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—testicular cancer	0.051	0.109	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—testicular cancer	0.0348	0.0744	CbGbCtD
Dihydroergotamine—CYP3A4—Vinblastine—testicular cancer	0.0339	0.0725	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—testicular cancer	0.0337	0.0721	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—testicular cancer	0.0306	0.0654	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—testicular cancer	0.0208	0.0446	CbGbCtD
Dihydroergotamine—Malaise—Etoposide—testicular cancer	0.000958	0.0018	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—testicular cancer	0.000955	0.00179	CcSEcCtD
Dihydroergotamine—Vertigo—Etoposide—testicular cancer	0.000955	0.00179	CcSEcCtD
Dihydroergotamine—Decreased appetite—Ifosfamide—testicular cancer	0.000954	0.00179	CcSEcCtD
Dihydroergotamine—Headache—Vinblastine—testicular cancer	0.000953	0.00179	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dactinomycin—testicular cancer	0.000947	0.00178	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dactinomycin—testicular cancer	0.000947	0.00178	CcSEcCtD
Dihydroergotamine—Fatigue—Ifosfamide—testicular cancer	0.000947	0.00178	CcSEcCtD
Dihydroergotamine—Oedema—Cisplatin—testicular cancer	0.000947	0.00178	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Bleomycin—testicular cancer	0.000946	0.00178	CcSEcCtD
Dihydroergotamine—Pain—Ifosfamide—testicular cancer	0.000939	0.00176	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000934	0.00175	CcSEcCtD
Dihydroergotamine—Tachycardia—Cisplatin—testicular cancer	0.000924	0.00174	CcSEcCtD
Dihydroergotamine—Asthenia—Bleomycin—testicular cancer	0.000922	0.00173	CcSEcCtD
Dihydroergotamine—Hypertension—Etoposide—testicular cancer	0.000917	0.00172	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Cisplatin—testicular cancer	0.000915	0.00172	CcSEcCtD
Dihydroergotamine—Pruritus—Bleomycin—testicular cancer	0.000909	0.00171	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ifosfamide—testicular cancer	0.000905	0.0017	CcSEcCtD
Dihydroergotamine—Nausea—Vinblastine—testicular cancer	0.000903	0.0017	CcSEcCtD
Dihydroergotamine—Anorexia—Cisplatin—testicular cancer	0.000902	0.00169	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—testicular cancer	0.000901	0.00169	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000898	0.00169	CcSEcCtD
Dihydroergotamine—Discomfort—Etoposide—testicular cancer	0.000894	0.00168	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—testicular cancer	0.000884	0.00166	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—testicular cancer	0.000883	0.00166	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Dactinomycin—testicular cancer	0.000883	0.00166	CcSEcCtD
Dihydroergotamine—Confusional state—Etoposide—testicular cancer	0.000874	0.00164	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—testicular cancer	0.000872	0.00164	CcSEcCtD
Dihydroergotamine—Urticaria—Ifosfamide—testicular cancer	0.000872	0.00164	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ifosfamide—testicular cancer	0.000868	0.00163	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ifosfamide—testicular cancer	0.000868	0.00163	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000862	0.00162	CcSEcCtD
Dihydroergotamine—Asthenia—Dactinomycin—testicular cancer	0.00086	0.00161	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—testicular cancer	0.000855	0.00161	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—testicular cancer	0.00085	0.0016	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000849	0.00159	CcSEcCtD
Dihydroergotamine—Tachycardia—Etoposide—testicular cancer	0.000846	0.00159	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—testicular cancer	0.000844	0.00159	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Etoposide—testicular cancer	0.000838	0.00157	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—testicular cancer	0.000833	0.00156	CcSEcCtD
Dihydroergotamine—Anorexia—Etoposide—testicular cancer	0.000827	0.00155	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—testicular cancer	0.000823	0.00155	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—testicular cancer	0.000822	0.00154	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dactinomycin—testicular cancer	0.00082	0.00154	CcSEcCtD
Dihydroergotamine—Vomiting—Bleomycin—testicular cancer	0.000817	0.00153	CcSEcCtD
Dihydroergotamine—Hypotension—Etoposide—testicular cancer	0.00081	0.00152	CcSEcCtD
Dihydroergotamine—Rash—Bleomycin—testicular cancer	0.00081	0.00152	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—testicular cancer	0.000809	0.00152	CcSEcCtD
Dihydroergotamine—Dermatitis—Bleomycin—testicular cancer	0.000809	0.00152	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ifosfamide—testicular cancer	0.000809	0.00152	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—testicular cancer	0.000807	0.00152	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000794	0.00149	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—testicular cancer	0.000792	0.00149	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—testicular cancer	0.000791	0.00149	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—testicular cancer	0.00079	0.00148	CcSEcCtD
Dihydroergotamine—Asthenia—Ifosfamide—testicular cancer	0.000788	0.00148	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—testicular cancer	0.00078	0.00147	CcSEcCtD
Dihydroergotamine—Paraesthesia—Etoposide—testicular cancer	0.000779	0.00146	CcSEcCtD
Dihydroergotamine—Pruritus—Ifosfamide—testicular cancer	0.000777	0.00146	CcSEcCtD
Dihydroergotamine—Dyspnoea—Etoposide—testicular cancer	0.000773	0.00145	CcSEcCtD
Dihydroergotamine—Somnolence—Etoposide—testicular cancer	0.000771	0.00145	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—testicular cancer	0.00077	0.00145	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—testicular cancer	0.000768	0.00144	CcSEcCtD
Dihydroergotamine—Nausea—Bleomycin—testicular cancer	0.000763	0.00143	CcSEcCtD
Dihydroergotamine—Vomiting—Dactinomycin—testicular cancer	0.000762	0.00143	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—testicular cancer	0.000761	0.00143	CcSEcCtD
Dihydroergotamine—Rash—Dactinomycin—testicular cancer	0.000755	0.00142	CcSEcCtD
Dihydroergotamine—Decreased appetite—Etoposide—testicular cancer	0.000754	0.00142	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ifosfamide—testicular cancer	0.000751	0.00141	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—testicular cancer	0.000748	0.00141	CcSEcCtD
Dihydroergotamine—Fatigue—Etoposide—testicular cancer	0.000748	0.0014	CcSEcCtD
Dihydroergotamine—Pain—Etoposide—testicular cancer	0.000742	0.00139	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—testicular cancer	0.000741	0.00139	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000735	0.00138	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—testicular cancer	0.000731	0.00137	CcSEcCtD
Dihydroergotamine—Dizziness—Ifosfamide—testicular cancer	0.000726	0.00136	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—testicular cancer	0.000726	0.00136	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—testicular cancer	0.000719	0.00135	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—testicular cancer	0.000715	0.00134	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Etoposide—testicular cancer	0.000715	0.00134	CcSEcCtD
Dihydroergotamine—Nausea—Dactinomycin—testicular cancer	0.000712	0.00134	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Etoposide—testicular cancer	0.000709	0.00133	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—testicular cancer	0.000705	0.00132	CcSEcCtD
Dihydroergotamine—Vomiting—Ifosfamide—testicular cancer	0.000698	0.00131	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—testicular cancer	0.000697	0.00131	CcSEcCtD
Dihydroergotamine—Rash—Ifosfamide—testicular cancer	0.000692	0.0013	CcSEcCtD
Dihydroergotamine—Dermatitis—Ifosfamide—testicular cancer	0.000692	0.0013	CcSEcCtD
Dihydroergotamine—Urticaria—Etoposide—testicular cancer	0.000689	0.00129	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—testicular cancer	0.000686	0.00129	CcSEcCtD
Dihydroergotamine—Abdominal pain—Etoposide—testicular cancer	0.000685	0.00129	CcSEcCtD
Dihydroergotamine—Body temperature increased—Etoposide—testicular cancer	0.000685	0.00129	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—testicular cancer	0.000685	0.00129	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—testicular cancer	0.000682	0.00128	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—testicular cancer	0.000681	0.00128	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—testicular cancer	0.000679	0.00128	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—testicular cancer	0.000679	0.00128	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—testicular cancer	0.000665	0.00125	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—testicular cancer	0.000662	0.00124	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—testicular cancer	0.000659	0.00124	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—testicular cancer	0.000656	0.00123	CcSEcCtD
Dihydroergotamine—Nausea—Ifosfamide—testicular cancer	0.000652	0.00123	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—testicular cancer	0.000648	0.00122	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—testicular cancer	0.000639	0.0012	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—testicular cancer	0.000638	0.0012	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—testicular cancer	0.000635	0.00119	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—testicular cancer	0.000635	0.00119	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00063	0.00118	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—testicular cancer	0.000628	0.00118	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—testicular cancer	0.000622	0.00117	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—testicular cancer	0.000614	0.00115	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—testicular cancer	0.000614	0.00115	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—testicular cancer	0.00061	0.00115	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—testicular cancer	0.000602	0.00113	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—testicular cancer	0.000597	0.00112	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—testicular cancer	0.000596	0.00112	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—testicular cancer	0.000593	0.00111	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—testicular cancer	0.00059	0.00111	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—testicular cancer	0.00059	0.00111	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—testicular cancer	0.000588	0.0011	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—testicular cancer	0.000584	0.0011	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—testicular cancer	0.000578	0.00109	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—testicular cancer	0.000574	0.00108	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—testicular cancer	0.000573	0.00108	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—testicular cancer	0.000573	0.00108	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—testicular cancer	0.000572	0.00107	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—testicular cancer	0.000568	0.00107	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—testicular cancer	0.000562	0.00106	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—testicular cancer	0.000553	0.00104	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—testicular cancer	0.000551	0.00104	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—testicular cancer	0.000547	0.00103	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—testicular cancer	0.000547	0.00103	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—testicular cancer	0.000546	0.00103	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—testicular cancer	0.000543	0.00102	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—testicular cancer	0.000542	0.00102	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—testicular cancer	0.000542	0.00102	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—testicular cancer	0.000541	0.00102	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—testicular cancer	0.000537	0.00101	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—testicular cancer	0.000535	0.00101	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—testicular cancer	0.000535	0.00101	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—testicular cancer	0.000535	0.00101	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—testicular cancer	0.00053	0.000995	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—testicular cancer	0.000526	0.000989	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—testicular cancer	0.000524	0.000984	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—testicular cancer	0.000515	0.000968	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—testicular cancer	0.000514	0.000966	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000511	0.00096	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—testicular cancer	0.000507	0.000952	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—testicular cancer	0.000507	0.000952	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—testicular cancer	0.000506	0.000951	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—testicular cancer	0.000505	0.000949	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—testicular cancer	0.000502	0.000943	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—testicular cancer	0.000501	0.000941	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—testicular cancer	0.000497	0.000933	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—testicular cancer	0.000496	0.000932	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—testicular cancer	0.000495	0.00093	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—testicular cancer	0.000495	0.00093	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—testicular cancer	0.00049	0.000921	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—testicular cancer	0.000487	0.000915	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—testicular cancer	0.000486	0.000913	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—testicular cancer	0.000485	0.000912	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—testicular cancer	0.000478	0.000898	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—testicular cancer	0.000476	0.000894	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—testicular cancer	0.000474	0.000891	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000473	0.000889	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—testicular cancer	0.00047	0.000883	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—testicular cancer	0.00047	0.000882	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—testicular cancer	0.000469	0.000881	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—testicular cancer	0.000469	0.000881	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—testicular cancer	0.000468	0.000878	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—testicular cancer	0.000466	0.000876	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—testicular cancer	0.000464	0.000871	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—testicular cancer	0.000463	0.00087	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—testicular cancer	0.000463	0.00087	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—testicular cancer	0.000462	0.000867	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—testicular cancer	0.000459	0.000862	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—testicular cancer	0.000457	0.000859	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—testicular cancer	0.000454	0.000853	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—testicular cancer	0.000453	0.000852	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—testicular cancer	0.000452	0.000848	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—testicular cancer	0.00045	0.000845	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—testicular cancer	0.000448	0.000841	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—testicular cancer	0.000444	0.000834	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000443	0.000832	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—testicular cancer	0.000442	0.000831	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—testicular cancer	0.00044	0.000826	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—testicular cancer	0.000439	0.000825	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—testicular cancer	0.000436	0.00082	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000435	0.000817	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—testicular cancer	0.000433	0.000814	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—testicular cancer	0.000432	0.000812	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—testicular cancer	0.000429	0.000805	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—testicular cancer	0.000428	0.000804	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—testicular cancer	0.000428	0.000804	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000425	0.000798	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—testicular cancer	0.000423	0.000794	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—testicular cancer	0.00042	0.000789	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—testicular cancer	0.000419	0.000787	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—testicular cancer	0.000416	0.000781	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—testicular cancer	0.000413	0.000775	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—testicular cancer	0.000411	0.000771	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—testicular cancer	0.000411	0.000771	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00041	0.00077	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—testicular cancer	0.000407	0.000764	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—testicular cancer	0.000404	0.000759	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—testicular cancer	0.000401	0.000753	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—testicular cancer	0.000401	0.000752	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—testicular cancer	0.0004	0.000751	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000397	0.000747	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—testicular cancer	0.000396	0.000744	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—testicular cancer	0.000391	0.000734	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—testicular cancer	0.000388	0.000728	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—testicular cancer	0.000386	0.000725	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—testicular cancer	0.000385	0.000722	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—testicular cancer	0.000384	0.000722	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—testicular cancer	0.000384	0.000722	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—testicular cancer	0.000383	0.000719	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—testicular cancer	0.000373	0.0007	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—testicular cancer	0.000371	0.000696	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000368	0.000691	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—testicular cancer	0.000367	0.00069	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—testicular cancer	0.000358	0.000673	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—testicular cancer	0.000357	0.000671	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—testicular cancer	0.000356	0.000668	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—testicular cancer	0.000356	0.000668	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—testicular cancer	0.000355	0.000668	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—testicular cancer	0.000349	0.000655	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—testicular cancer	0.000344	0.000646	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—testicular cancer	0.000343	0.000645	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—testicular cancer	0.000333	0.000625	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—testicular cancer	0.000331	0.000622	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—testicular cancer	0.00033	0.00062	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—testicular cancer	0.000327	0.000615	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—testicular cancer	0.000327	0.000615	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—testicular cancer	0.000325	0.000611	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—testicular cancer	0.000323	0.000606	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—testicular cancer	0.000321	0.000604	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—testicular cancer	0.000318	0.000598	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—testicular cancer	0.000309	0.000581	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—testicular cancer	0.000309	0.00058	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—testicular cancer	0.000308	0.000578	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—testicular cancer	0.000306	0.000576	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—testicular cancer	0.000306	0.000575	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—testicular cancer	0.000305	0.000572	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—testicular cancer	0.000297	0.000559	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—testicular cancer	0.000289	0.000542	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—testicular cancer	0.000286	0.000537	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—testicular cancer	0.000284	0.000533	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—testicular cancer	0.000283	0.000532	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—testicular cancer	0.000282	0.000529	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—testicular cancer	0.000267	0.000502	CcSEcCtD
